5'-脱氧-5-氟尿苷（5'-DFUR）在晚期癌症患者中的临床试验
[Clinical trial of 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced cancer patients].
作者信息
Irie K, Yasutake K, Imamura Y, Yoshimura Y, Yoshida M, Nakamura T, Suehiro I
出版信息
Gan To Kagaku Ryoho. 1985 Dec;12(12):2371-8.
5'-DFUR was administered orally to advanced or recurrent cancer patients at a daily dosage of 600-1200 mg divided into 3 or 4 times a day. Out of 13 evaluable cases 2PR, 2MR, 4NC and 5PD were observed, response rate was 15.4%. PR were obtained in one gastric cancer case and one breast cancer case. Side effects were observed in 6 cases out of 14 cases (42.9%) and major adverse reaction was gastro-intestinal toxicities such as anorexia, nausea-vomiting and diarrhea. Two leukocytopenia and one erythrocytopenia were observed. This study indicated that 5'-DFUR would be useful as a new anticancer agent.
对晚期或复发性癌症患者口服5'-去氧氟尿苷，每日剂量为600 - 1200毫克，分3或4次服用。在13例可评估病例中，观察到2例部分缓解（PR）、2例疾病稳定（MR）、4例疾病无进展（NC）和5例疾病进展（PD），缓解率为15.4%。1例胃癌病例和1例乳腺癌病例获得了部分缓解。14例中有6例（42.9%）观察到副作用，主要不良反应是胃肠道毒性，如厌食、恶心呕吐和腹泻。观察到2例白细胞减少和1例红细胞减少。本研究表明，5'-去氧氟尿苷可作为一种新型抗癌药物。
Zotero 插件